Despite decades of investigations and accumulated scientific knowledge, preterm birth (PTB) remains a significant burden worldwide. Several mechanisms have been proposed to explain this condition, and a number of risk factors from infectious to behavioral and genetic/epigenetic factors influence this outcome. The heritability of PTB is estimated to be 17% to 36%, which demonstrates that genetic predisposition plays a key role in PTB. Structural DNA modifications without changes in the DNA sequence and post-transcriptional regulation also have an impact on gene expression and thus influence pregnancy outcomes. There is a complex interplay between environmental factors and the individual's genetics and epigenetics that may culminate in PTB, but the complete regulatory pathways and networks involved in this context are still unclear. Here, we outline what is known so far about the genetic and epigenetic factors involved in preterm delivery, including polymorphisms, DNA methylation, and microRNAs, and suggest fields for research.
Although common causes of PTB, infections and smoking status are unable to completely explain the high rates of prematurity worldwide. Other reported risk factors for PTB include advanced maternal age (over 40), extreme body mass index (<18.5 or >35 kg/m 2 ) and, importantly, genetic predisposition. 16 It is very likely that genetic predisposition may help explain most of the remaining cases and even contribute to those in which other risk factors are present. It has been demonstrated that genetic factors play a key role in PTB. Mothers with previous or family history of PTL or PPROM are at risk of the reoccurrence of these complications. 17, 18 Twin studies estimate the heritability of PTB as 17% to 36%. 19, 20 Other evidence linking genetic predisposition, epigenetic/environmental contributions, and PTB includes the striking difference among PTB rates in different ethnic groups. 21, 22 Furthermore, a large meta-analysis has recently emphasized the impact of genetic and epigenetic traits in gestational outcomes as prior PTB was found to be the strongest individual risk factor for this complication in a data set comprising 4.1 million births. 16 Unlike Mendelian diseases caused by highly penetrant gene mutations in a single gene, PTB is rather influenced by several concurrent mutations in different genes and by gene-environment interactions. Large-scale gene expression profiling and genome-wide studies have identified altered expression and genetic polymorphisms in several proinflammatory, angiogenic, and tissue turnover-related genes in placentas from pregnancies complicated by PTL when compared to normal term deliveries. 11, 23, 24 Most of these studies have reported an influence of the fetal genome in the predisposition to PTB although to a lesser extent than the influence of maternal genetic factors. 25, 26 Moreover, several studies have shown that modifications not only in the DNA sequence but also in its structure, that is, epigenetic changes, can affect the gestational outcome. 27, 28 It seems clear that there is a complex interplay between environmental factors (ie, infections and others) and the individual's genetic and epigenetic settings that may culminate in PTB, but the complete regulatory pathways and networks involved in this context are still unclear. Here, we outline what is known so far about the genetic and epigenetic involvement in preterm delivery in terms of polymorphisms, microRNAs (miRNA), and DNA methylation and suggest fields for research.
Single-Nucleotide Polymorphisms and PTB

Polymorphisms in Proinflammatory Genes
As inflammation has been postulated to be the major mechanism causing PTL and PPROM, and consequently PTB, one could expect molecules involved in the regulation of the innate immune response to be chosen as targets of genetic studies in PTB. Another gene set that has been largely evaluated in such studies are those involved in the synthesis and degradation of the extracellular matrix considering their role in the integrity of chorioamniotic membranes. Single-nucleotide polymorphisms (SNPs) in these genes often affect protein expression and may modulate PTB. As the main source of genetic variability in human genome, SNPs have been extensively studied in pregnancy complications.
Cytokines
Interleukin 1 beta (IL-1b) is the prototypic proinflammatory cytokine and has been consistently associated with PTL. High intra-amniotic levels of IL-1b induce the synthesis of prostaglandin E2 by cyclooxygenase 2 and consequently lead to myometrial contractility and labor. Studies have reported associations between PTB and specific SNPs in this gene, such as the maternal IL1B-511 TT genotype. 29 Similarly, the IL1Bþ3953 C>T polymorphism was associated with a reduced risk of PTB in Austrian Caucasian women in a study by Schmid et al. 30 The SNPs in the gene that encodes for IL-1a, a cytokine from the same family as IL-1b, were screened by Yilmaz et al, 29 and the fetal IL1A-4845 TT genotype was shown to be an independent risk factor for PTB in a Turkish population. Interleukin 1 beta and IL-1a bind to IL-1 receptor to trigger the inflammatory cascade. A polymorphism located in the gene that encodes for the IL-1 receptor antagonist, an inhibitor of IL-1b activity, was reported to increase the odds of PTB when both mother and child carried the IL-1RN allele 2 among nonHispanic white women in Michigan (United States) in a large cohort of 1371 pregnant women. 31 Genetic alterations were also investigated within TNFA, which encodes for TNF-a, an important modulator of pregnancy. The variation in the promoter region at position À308 is by far the most studied SNP. Although some authors have not observed any association between this SNP and PTB, 29, 32 the majority of studies link the TNFA-308 A allele to PTB. [33] [34] [35] Our group has recently reported a protective role against PPROM and PTL for the low-producing TNF-238 A allele and TNFA-308G-238 A haplotype in samples from Brazilian women. 12 Findings by Liang et al 35 suggest that one TNFA-308 G allele and therefore the monoallelic full expression of TNF-a is protective against PTB. Several studies evaluated polymorphisms in the TNF receptor, and it was observed that the risk of PTB was higher among African American women when both mother and child carried the TNFR2 allele. 31 Another target for SNP studies in this field is the cytokine considered to be the main predictor of PTL, IL-6, a cytokine also associated with PPROM. 36, 37 The À174 polymorphism in the promoter region alters protein expression and has been linked to PTL in Polish women in the presence of the in tandem polymorphism IL1RN*2. 38 Velez et al 39 correlated variations in IL6 and IL6R genes with IL-6 concentration in amniotic fluid in Caucasian fetal samples and African American maternal samples of patients with PTB. Various other cytokines regulate birth timing. Speer et al 40 correlated the mutant fetal allele for interferon g (IFN-g), which produces high levels of the protein, to the PTB phenotype, conditioned on maternal genotype from American population, thus demonstrating the importance of maternal-fetal and environmental interactions. It is rather likely that a combination of different polymorphisms in a number of proinflammatory genes predispose to adverse gestational outcomes. Haplotype analysis in Brazilian population demonstrated association between the TNFA GG/IL-6 GG/IFNG AA and susceptibility to PTB. 33 
Toll-Like Receptors
A specific set of bacterial epitopes, the pathogen-associated molecular patterns (PAMPS), are recognized by TLR, a class of pattern recognition receptors (PRRs). Human trophoblast cells express TLR 1, 2, 3, 4, 5, 6, 9 and 10, which seem to be regulated in a temporal manner throughout pregnancy. [41] [42] [43] As mentioned before, binding of PAMPS to TLR dimers initiates the production of inflammatory mediators via NF-kB, leading to the inflammatory events that culminate in PTB.
In a study performed with Brazilian women who underwent PTL and PPROM, our group described the association between a polymorphism in TLR2 (rs4696480) and increased risk of PPROM. 12 Such allele was previously associated with risk of sepsis by gram-positive bacteria. 44 In a Polish population, Bitner et al 45 studied polymorphisms in TLR4 that lead to lower production of IL-1a after lipopolysaccharide (LPS) stimulation. 46 The authors observed that maternal carriage of the hyporesponsive TLR4-1196 T allele, but not for another hyporesponsive allele TLR4-896G, was associated with reduced risk of PTB before the 33rd week of gestation. 45 
Other Genes
A whole set of polymorphisms in other genes involved in several system pathways have also been linked to PTB. Polymorphisms in genes related to the endocrine system can lead to structural changes in the uterus and the cervix that are hormone-mediated. A functional decrease in progesterone levels is a mechanism of loss of uterine quiescence, and SNPs in the progesterone receptor have been associated with PTB by some studies such as the G allele in rs471767, 47, 48 although some authors did not observe this association. 49 Regarding oxytocin, an inducer of myometrial contractility, a research group in Austria 50 observed that a specific haplotype combination (rs2254298 A allele, rs2228485 C allele, and rs237911 G allele) was significantly associated with increased risk of PTB, but when analyzed separately, none of these SNPs were associated with this complication. By linkage analysis, Haataja et al 51 identified the gene that encodes for insulin-like growth factor receptor 1 as a potential PTB-predisposing gene among families of Finnish origin. The same group found that a CAG repeat polymorphism located within exon 1 of the AR gene in the offspring is associated with PTB. 52 Polymorphisms in genes that regulate other body systems such as tissue remodeling, angiogenesis, and metabolism have also been studied in patients with PTB but represent a less common source of risk of this pathology. 53 These studies show that genes involved in multiple pathways determine the heterogeneity of PTB and may also contribute to PTB susceptibility.
Maternal Inheritance
Contributing to the notion that genetic inheritance underlies adverse gestational outcomes, it has been hypothesized that polymorphisms in mitochondrial DNA could increase the risk of PTL and PPROM. Although epidemiological studies have indicated that the recurrence of PTB is maternally associated, suggesting that mitochondrial variants may contribute to the risk of PTB, the investigation of mitochondrial SNPs by genome-wide association study (GWAS) showed no association with PTL or PPROM after a meta-analysis in a study on Danish and Norwegian populations. 54 The authors discuss other mechanisms of maternal inheritance not yet investigated such as gene imprinting. Nonetheless, an evaluation regarding mitochondrial polymorphisms and PTB merits further investigations.
Despite all these efforts, scientists are yet to find a "genetic preterm signature" able to confidently predict the gestational outcome, as many of these studies have provided heterogeneous results concerning the effect of specific polymorphisms in PTB. This is partially explained by the variety of methods used in these studies and by the differences in the populations evaluated, especially because most studies do not perform a biological evaluation of genetic background and only take into consideration self-reported ethnicity, which has very limited reliability for most populations. 55 Moreover, the heterogeneity of PTL may cloud significant findings. Additionally, combined maternal and fetal haplotypes and their interactions are rarely taken into consideration. The application of homogeneous methods and accurate ethnic discrimination may provide more reliable information in the near future when genetic studies should be specifically validated for each population. What seems to be relatively consistent so far as for the role of SNPs in the development of PTB is the presence of certain alleles repeatedly described in women with PTB across the globe, such as the alleles IL6 À174 G and TNFA À308 A. [33] [34] [35] 38 A summary of the studies cited here is listed in Table 1 .
The Role of Epigenetics in PTB
Epigenetics refers to modifications to the DNA structure without changes in the DNA sequence, which produce heritable and stable, but potentially reversible, alterations in the transcriptional potential of a cell. A number of recent studies have supported the hypothesis that epigenetic alterations induced by pregnancyrelated risk factors may influence the risk of PTB.
DNA Methylation and Chromatin Remodeling
The addition of methyl groups at position 50 of the cytosine pyrimidine ring in CpG dinucleotides converts cytosine to 5-methylcytosine. Highly methylated areas of the genome, especially in promoter regions, can disrupt transcription factor binding and therefore are less transcriptionally active. These changes lead to chromatin remodeling and transcriptional silencing. 
Changes in DNA methylation patterns have already been described in adverse pregnancy outcomes. Wang et al 27 demonstrated that epigenetic regulation by DNA methylation at MMP1 promoter correlates with its expression in the amnion and with the susceptibility to PPROM. Lower methylation in the MICB gene in peripheral leukocytes was reported in African American women who underwent PTB in comparison to women who delivered at term. MICB is a constituent of major histocompatibility complex class I involved in the initiation of immune responses; the reduced methylation observed in patients with PTB leads to increased expression of this gene. 56 Kim et al 28 investigated genome-wide methylation signatures that could distinguish between term and preterm patients using amniotic tissues from women in Argentina and in the United States. They identified that gene sets involved in the modulation of cellular behavior and tissue maintenance and organization are differently methylated between PTB and term delivery groups, which is in line with the importance of intact fetal membranes in the maintenance of pregnancy. Differential methylation patterns were also reported in fetal samples. Preterm and term neonates were shown to present distinct DNA methylation patterns in leukocytes from umbilical cord blood. 57 Environmental factors are strongly associated with epigenetic modulation. For instance, the epigenome can be modified by diet. Folate and vitamin B 12 are methyl donors, and the deficiency of these micronutrients correlates with altered DNA methylation. 58, 59 Moreover, low folate intake during pregnancy is a well-known risk factor for neural tube defects, and observational studies have indicated that adequate levels of this nutrient are associated with higher birth weight and fewer preterm births. 60, 61 In that way, it seems plausible that an inappropriate diet could facilitate PTB by still not completely known epigenetic mechanisms.
Two large studies have shown that environmental exposure has a strong impact on birth timing. Porter et al 62 studied women in Alabama and concluded that those living within 5 km of high-polluting plants had a 5-fold higher risk of presenting with PTB when compared to those outside these areas, even after adjustments for age, socioeconomic status, and ethnicity. Similarly, Ferguson et al 63 demonstrated that American women with high blood levels of phthalate metabolites (substances found in food and cosmetics) had increased odds of PTB regardless of other risk factors. While there is still much to learn regarding the mechanisms by which environmental exposures alter epigenetics and thus predispose to adverse gestational outcome, studies in this area hold the promise of having a direct positive impact on PTB rates, since epigenetic risks are modifiable risks.
Importantly, these changes in methylation may result in long-term consequences. In experimental models, it was shown that toxins such as bisphenol A (BPA) alter DNA methylation in the mouse uterus and that these alterations, while reversible upon dietary intervention, may persist for 2 subsequent generations. 64 Burris et al 65 found that improving the perinatal environment is critical, as it affects not only the exposed fetus but also subsequent generations. Moreover, it is worth noting that the epigenetic changes that occur in the fetus during development are partially responsible for the early onset of adult diseases observed in preterm neonates. 66 DNA methylation is heritable to a certain degree. By comparing methylation status across the genome from mothers and unrelated fetuses, Parets et al 56 identified over 5000 CpG sites in which maternal and fetal methylation were associated. The authors reported that these sites were more likely to be located in genes that modulate cardiovascular, metabolic, and immune pathways, which is in agreement with the hypothesis of the developmental origin of health and disease which states that the perinatal environment affects adult health. Moreover, most of these CpG sites overlapped SNPs, which partly explains the hereditability of methylation and indicates the accumulated influence of polymorphisms in gestational outcome and the intricate relationship between epigenetic mechanisms and gene expression.
While a long-term epigenetic signature has been suggested for PTB, 56 until present, it is not clear whether differential Abbreviations: AR, Androgen receptor; IFNG, interferon gamma; IL1A, interleukin 1 alpha; IL1B, interleukin 1 beta; IL1RN, interleukin 1 receptor antagonist; IL2RG, interleukin-2 receptor gamma subunit; IL6, interleukin 6; IGF1 R, insulin-like growth factor receptor 1; KCNN3, small conductance calcium activated potassium channel isoform 3; matþfet, maternal and fetal samples; MBL, mannan-binding lectin, MMP9, metalloproteinase 9; OXT, oxytocin; OXTR, oxytocin receptor; PCRþRFLP, Polymerase chain reaction followed by restriction fragment length polymorphism; PGR, progesterone receptor; PTB, preterm birth; PTL, preterm labor; PPROM, preterm premature rupture of membranes; SSP-PCR, single specific primer polymerase chain reaction; TGFB, transforming growth factor beta 1; TLR4, Toll-like receptor 4; TNFRSF6, Fas; TNF, tumor necrosis factor; TNFRII, tumor necrosis factor receptor 2.
methylation is a reflection of developmental differences or to what extent they may lead to long-term consequences, a question that can only be elucidated by future longitudinal studies.
MicroRNAs
MicroRNAs are small (20-22 nucleotides) non-coding RNAs that modulate gene expression in many physiological settings by destabilizing or inhibiting the translation of target messenger RNA (mRNAs) at the posttranscriptional level. 67 The miRNAs form the RNA-induced silencing complex (RISC) that binds to the 3 0 untranslated region (3 0 -UTR) of specific target genes to regulate their expression. Alternatively, it has been recently shown that the RISC complex may bind to the 5 0 -UTR, possibly acting to stabilize the target mRNA. 68 A large number of miRNAs have been identified and/or predicted, and in humans it is estimated that 30% to 50% of genes are potential targets for miRNA regulation.
69,70 miRNAs were first described in 1980, but it was not until recently that these molecules started to gain visibility in the context of pregnancy. Not only can the study of these molecules enhance our knowledge concerning the pathogenesis of prematurity, but they have also emerged as potential biomarkers and therapeutic tools against PTB and PPROM.
MicroRNAs are expressed in the placenta and can be detected in gestational tissues and maternal plasma. Three miRNA clusters are specifically related to placental development: the chromosome 14 miRNA cluster (C14MC), the C19MC, and the miR-371 cluster. The miRNAs have been recently reported to play a role in the regulation of normal labor as well as in prematurity. 71, 72 Molecules from the miRNA-200 family regulate the expression of zinc-finger E-box binding homeobox proteins ZEB1 and ZEB2. These 2 crucial proteins suppress the expression of the oxytocin receptor and connexin 43 prior to the onset of labor, thereby maintaining uterine quiescence, 73 and have been demonstrated to block oxytocininduced contractility in human myometrial cells. 74 A study by Elovitz et al 75 associated increased expression of miR-145, miR-143, and miR-199 in cervical cells in American women with cervical remodeling that delivered preterm. The authors suggested that increased miR-145 leads to a decrease in the adhesion protein JAM-A, thus increasing the permeability of the epithelial barrier in the cervix and favoring PTL. In a study on 56 Mexican pregnant women, higher expression of 6 cervical miRNAs, that is, miR-21, 29b, 30e, 142, 148b, and 223 of 800 miRNAs profiled were significantly associated with a shorter length of gestation after adjustment for age, education, body mass index, parity, and smoke exposure; 5 of those (miR-21, 29b, 30e, 142, and 148b) were differently expressed in preterm when compared to term pregnancies. 76 The mRNA targets for these miRNAs are involved in innate and adaptive immune responses, especially with the TNF-induced inflammatory response and DNA methyltransferases that regulate DNA replication. This latter observation illustrates the interconnection between these 2 epigenetic mechanisms, that is, miRNAs and DNA methylation, and their involvement in the preterm termination of pregnancy. Despite the need for larger prospective studies, the reproducibility of findings reported by these 2 studies performed with distinct populations during second-trimester pregnancies indicate that these local miRNAs have great potential to be used as noninvasive cervical biomarkers for PTB in the near future, at least for PTB phenotypes associated with cervical changes.
Systemically, however, the results available in the literature so far do not seem as promising. A recent study found that miRNA profiles in serum were not different between women with PTL and women who delivered at term, although the sample population of this study was small, and the authors did not investigate miRNAs encapsulated by extracellular vesicles or attached to argonaute protein, forms that increase miRNA stability in the circulation. 75 Altered levels of miR-338, miR-199a-3p, and miR-223 have been associated with PTL in other gestational tissues. miR-338 targets PLA2G4B mRNA, which is translated into phospholipase A2. The chorioamniotic membranes of PTL patients present decreased expression of this miRNA, leading to increased levels of phospholipase A2, which results in increased prostaglandin synthesis that in turn initiates the PTL cascade. 72 Acting in this same pathway, decreased expression of miR-199a-3p in mouse myometrium increases prostaglandin production by reducing the suppression of cyclooxygenase 2. 77 In a recent study, miR-223 levels in the amnion were inversely associated with the risk of PTL and PPROM. 78 Although functional analyses were not performed in this study, targets for miR-223 include a number of genes involved in the same pathways activated in PTL and PPROM, including inflammation, immune cell responses, and hematopoietic differentiation. 79 As intracellular modulators of gene transcription, miRNAs also have an impact on the response to pathogens and therefore may be implicated in infection-associated adverse gestational outcomes, as demonstrated by Garg et al. 80 Nuclear factor-kB is a heterodimer composed of 2 subunits from p65 (RelA), Rel-B, c-Rel, p52, and/or p50. 81 Upon activation, NF-kB enters the nucleus to regulate gene expression. Using culture methods, authors have identified an miRNA that regulates NF-kB p65 mRNA, the miR-329. This miRNA regulates TLR2-mediated apoptosis induced by the administration of peptidoglycan (PDG) from gram-positive bacteria in first-trimester TLR6 trophoblasts. PDG upregulates miR-329, which targets NF-kB p65 mRNA, thus decreasing expression of IL-6 and leading to apoptosis. miR-23a and let-7c have also been identified to play a part in IL-6 inhibition under these conditions. By inference, miR-329, miR-23a, and let-7c may be important factors in triggering placental injury and adverse pregnancy outcomes as modulators of TLR-mediated inflammation and apoptosis at the maternal-fetal interface.
Additionally, some miRNAs such as miR-16, 20a, 26b, 29b, 144, 146b-5p, 155, 210, and 335 have been found to present altered expression under experimental conditions of oxidative stress. [82] [83] [84] Unopposed reactive oxygen species (or oxidative stress [OS] ) and the consequent oxidative damage are wellknown mechanisms involved in PTL and especially in PPROM. 85, 86 Although it is possible that these molecules could be implicated in OS-induced PTB, the role of these miRNAs in OS-induced pathways in the setting of prematurity is yet to be investigated.
Undoubtedly, miRNAs add more complexity to the finetuned regulation of birth onset, and there is still much to be explored concerning their mechanisms of action. Importantly, the discovery of new miRNAs involved in the regulation of birth timing increases the possibility of approaches to PTL prediction and to new therapeutic targets. More investigations regarding the biological effect of miRNAs will bring new insight into the epigenetic regulation of physiological and pathological termination of pregnancy.
Conclusion
In combination, genomic and epigenomic profiles may provide valuable insight into the mechanisms underlying pregnancies complicated by PTL and PPROM. More systematic and unbiased genetic and epigenetic approaches are needed in future studies to enhance our understanding of the genetic and epigenetic basis of human birth timing and hopefully provide knowledge that can be translated into clinical practice.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
